Abstract
The bisphosphonate ibandronate, administered either daily or intermittently with an extended between-dose interval of >2 months, has been shown to reduce significantly the incidence of vertebral fractures, to increase bone mineral density and to reduce levels of biochemical markers of bone turnover in a phase III randomized study in women with postmenopausal osteoporosis (PMO). Bone histomorphometry was performed on a subgroup of women participating in this study in order to assess bone quality and architecture. The patients were randomized to receive one of the following: placebo, continuous oral daily ibandronate (2.5 mg/day) or intermittent oral ibandronate (20 mg every other day for 12 doses every 3 months). Out of the overall study population of 2,946 patients, 110 were randomly assigned to undergo transiliac bone biopsy at either month 22 or month 34 of treatment. The primary safety endpoint was osteoid thickness in trabecular bone, which was measured to exclude treatment-induced bone mineralization defects. Secondary safety endpoints assessed bone volume, bone turnover and micro-architecture. The primary efficacy endpoint was bone mineralizing surface. In all bone biopsy cores, newly formed trabecular bone retained its structure without any signs of woven bone. Marrow fibrosis and signs of cellular toxicity were not observed. Quantitative assessment demonstrated no impairment in mineralization of bone matrix: osteoid thickness tended to be similar or slightly lower in the ibandronate groups versus the placebo group. All secondary safety variables and the bone efficacy parameter were consistent with the production of normal-quality, newly formed bone and a modest reduction in bone turnover with both ibandronate regimens relative to placebo. Long-term treatment with oral ibandronate, even when administered with an extended between-dose interval of >2 months, produces normal-quality, newly formed bone in women with PMO.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Frost HM (1969) Tetracycline based histological analysis of bone remodelling. Calcif Tissue Res 3:211–237
Delmas P, Recker R, Stakkestad JA, et al (2002) Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: results from a pivotal phase III study (abstract). Osteoporos Int 13 [Suppl 1]:S15
Chavassieux PM, Arlot M, Meunier PJ (2001) Clinical use of bone biopsy. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, San Diego, pp 501–509
Parfitt AM, Drezner MK, Glorieux FH, et al (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610
Chavassieux PM, Arlot ME, Reda C, et al (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475–1480
Compston JE, Vedi S, Stellon AJ (1986) Inter-observer and intra-observer variation in bone histomorphometry. Calcif Tissue Int 38:67–70
Chavassieux PM, Arlot ME, Meunier PJ (1985) Intersample variation in bone histomorphometry: comparison between parameter values measured on two contiguous transiliac bone biopsies. Calcif Tissue Int 37:345–350
de Vernejoul MC, Kuntz D, Miravet L, Goutallier D, Ryckewaert A (1981) Bone histomorphometric reproducibility in normal patients. Calcif Tissue Int 33:369–374
Bergot C, Laval-Jeantet AM, Laval-Jeantet M (1978) Etude critique des variations de la mesure de la masse osseuse par biopsie iliaque. Rev Rhum Mal Osteoartic 45:317–324
Bravenboer N, Papapoulos SE, Holzmann P, Hamdy NA, Netelenbos JC, Lips P (1999) Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteoporos Int 9:489–493
Eriksen EF, Melson F, Sod E, Chines A, Law L (2001) The effect of 5-year risedronate therapy on bone histology and histomorphometry (abstract). J Bone Miner Res 16 [Suppl 1]:S218
Reid IR, Brown JP, Burckhardt P, et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661
Marcus R, Majumdar S (2001) The nature of osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, San Diego, pp 3–17
Monier-Faugere MC, Geng Z, Paschalais E, et al (1999) Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 14:1768–1778
Smith SY, Recker RR, Hannan M, Müller R, Bauss F (2003) Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32:45–55
Acknowledgements
This trial was sponsored by F. Hoffmann-La Roche Ltd., Basel, Switzerland. The authors wish to recognize the help of the histomorphometry technicians, Susan Bare and Toni Howard.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Recker, R.R., Weinstein, R.S., Chesnut, C.H. et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 15, 231–237 (2004). https://doi.org/10.1007/s00198-003-1530-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-003-1530-0